Systemic treatment for BRAF-mutant melanoma: Where do we go next?

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages

  Menzies, Alexander M ^a,b   Long, Georgina V ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; BGJ 398; BINIMETINIB; BMS 93655; BMS 936559; BUPARLISIB; BYL 719; CABOZANTINIB; COBIMETINIB; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; DACTOLISIB; GANITUMAB; INC 280; IPILIMUMAB; LEE 011; LGX 818; LY 2835219; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MK 8353; MPDL 3280 A; NIVOLUMAB; P 1446 A 05; P 276 00; PALBOCICLIB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PLX 7904; PROTEIN TYROSINE KINASE INHIBITOR; RO 5045337; SAR 245409; TRAMETINIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ALOPECIA; ARTHRALGIA; BRAF GENE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; EARLY CANCER; ENZYME BLOOD LEVEL; EYE TOXICITY; FATIGUE; FEVER; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; KERATOACANTHOMA; KIDNEY DISEASE; LIVER TOXICITY; MELANOMA; MONOTHERAPY; MYALGIA; ONCOGENE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; VITILIGO; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904888606     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70072-5     Document Type: Review

References (91)

1. Jang S, Atkins MB Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 2013, 14:e60-e69.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. the BRIM-3 Study Group.
3. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
4. Kim K, Ribas A, Chmielowski B, et al. Long term safety and efficacy of vemurafenib in the treatment of BRAFV600-mutant advanced melanoma (BRIM-2 study update). Pigment Cell Melanoma Res 2012, 25:866. (abstract).
5. V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
6. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013, 31:3205-3211.
7. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013, 31:1767-1774.
8. Corcoran RB, Rothenberg SM, Hata AN, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013, 5:196ra98.
9. Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013, 19:4868-4878.
10. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
11. 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer 2013, 49:395-402.
12. Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013, 3:350-362.
13. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
14. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
15. Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res 2014, published online Jan 24. 10.1158/1078-0432.CCR-13-3122.
16. Romano E, Pradervand S, Paillusson A, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 2013, 19:5749-5757.
17. Wilmott JS, Tembe V, Howle JR, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012, 11:2704-2708.
18. Kim KB, Flaherty KT, Chapman PB, et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 8519.
19. Chan M, Haydu L, Menzies AM, et al. Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor dabrafenib or vemurafenib beyond disease progression. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9062.
20. Azer MWF, Menzies AM, Haydu LE, Kefford RF, Long GV Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 2014, 120:530-536.
21. Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013, 31:e283-e287.
22. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013, 31:e220-e222.
23. Carlino MS, Gowrishankar K, Saunders CA, et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013, 12:1332-1342.
24. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
25. Kang Y-K, Ryu M-H, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013, 14:1175-1182.
26. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014, published online Feb 27. 10.1002/cncr.28620.
27. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012, 10:107.
28. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
29. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
30. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012, 30:2375-2383.
31. Zimmer L, Haydu LE, Menzies AM, et al. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol 2013, published online Dec 2. 10.1200/JCO.2013.49.5572.
32. Chapman PB, Metz D, Sepulveda A, et al. Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res 2012, 25:847. (abstract).
33. Menzies AM, Kefford RF, Long GV Paradoxical oncogenesis: are all BRAF inhibitors equal?. Pigment Cell Melanoma Res 2013, 26:611-615.
34. Dummer R, Rinderknecht J, Goldinger SM Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012, 366:480-481.
35. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013, 368:1365-1366.
36. Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9028.
37. Le K, Blomain ES, Rodeck U, Aplin AE Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res 2013, 26:509-517.
38. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
39. Maio M, Bondarenko I, Robert C, et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. The European Cancer Congress 2013; Amsterdam, Netherlands; Sept 27-Oct 1, 2013. Abstract 3704.
40. Flaherty KT, Sosman J, Atkins MB New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. American Society of Clinical Oncology 2012 Educational Book 2012, American Society of Clinical Oncology, Alexandria, VA.
41. Amaravadi R, Kim K, Flaherty K, et al. Prolonged responses to vemurafenib in patients with BRAFV600-mutant melanoma with low tumor burden at baseline. Pigment Cell Melanoma Res 2011, 24:1024. (abstr P3).
42. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9013.
43. Kim K, Amaravadi RK, Flaherty K, et al. Significant long-term survival benefit demonstrated with vemurafenib in ongoing Phase I study. Pigment Cell Melanoma Res 2012, 25:866. (abstract).
44. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010, 102:1724-1730.
45. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
46. Daud A, Weber J, Sosman J, et al. Overall survival update for BRF113220 Part C, a Phase II three-arm randomized study of dabrafenib alone (D) vs. a combination of dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive metastatic melanoma. Society for Melanoma Research 2013 International Congress; Philadelphia, PA, USA; Nov 17-20, 2013.
47. V600-mutated melanoma: a phase 1b study. Lancet Oncol 2014, 15:954-965.
48. Kefford R, Miller WH, Tan DS-W, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9029.
49. Menzies AM, Lee CI, Haydu LE, et al. Clinical correlates and management of pyrexia in patients (pts) treated with dabrafenib combined with trametinib (CombiDT) for V600 BRAF-mutant metastatic melanoma. Pigment Cell Melanoma Res 2012, 25:873. (abstract).
50. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
51. Sosman JA, Daud A, Weber JS, et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9005.
52. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013, 31:482-489.
53. Goldinger SM, Zimmer L, Schulz C, et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer 2014, 50:406-410. the Dermatology Cooperative Oncology Group (DeCOG).
54. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2013, 2:e00747.
55. Menzies AM, Haydu LE, Carlino MS, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One 2014, 9:e85004.
56. Wagle N, Van Allen EM, Frederick DT, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9015.
57. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
58. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Proc Am Soc Clin Oncol 2013, 31. abstr CRA9006.
59. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
60. Robert C, Hamid O, Ribas A, et al. Updated clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in advanced melanoma. Pigment Cell Melanoma Res 2013, 26:993. (abstract).
61. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9010.
62. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
63. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
64. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 3016.
65. Klein O, Ribas A, Chmielowski B, et al. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013, 31:e215-e217.
66. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
67. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
68. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
69. Kwong LN, Davies MA Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 2013, 19:5310-5319.
70. Xing F, Persaud Y, Pratilas CA, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012, 31:446-457.
71. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760.
72. Carlino MS, Todd JR, Gowrishankar K, et al. Differential sensitivity of melanoma with acquired BRAF inhibitor resistance to MEK and ERK inhibition. Pigment Cell Melanoma Res 2013, 26:992. (abstract).
73. Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013, 3:742-750.
74. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
75. Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ Induction of cyclin D1 overexpression by activated ras. Oncogene 1994, 9:3627-3633.
76. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
77. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
78. Petrella T, Verma S, Spithoff K, Quirt I, McCready D Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol 2012, 24:413-423. the Melanoma Disease Site Group.
79. Hoshimoto S, Faries MB, Morton DL, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 2012, 255:357-362.
80. Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
81. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117:1687-1696.
82. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
83. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50:611-621.
84. Kefford RF, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Pigment Cell Melanoma Res 2013, 26:965. (abstract).
85. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.
86. Bahadoran P, Allegra M, Le Duff F, et al. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol 2013, 31:e324-e326.
87. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013, 49:1073-1079.
88. Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012, 2:791-797.
89. Gentilcore G, Madonna G, Mozzillo N, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 2013, 13:17.
90. Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 2012, 7:e29336.
91. Katona TM, Jones TD, Wang M, Eble JN, Billings SD, Cheng L Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol 2007, 31:1029-1037.